Aurobindo Pharma

Aurobindo Pharma EBITDA per Share

The EBITDA per Share of Aurobindo Pharma (AUROPHARMA.NS) as of Nov 6, 2026 is 95.06 INR. In the previous year, EBITDA per Share was 123.23 INR — a change of -22.86% (lower).

EBITDA per Share

95.06INR

YoY

-22.86%

Last updated:

EBITDA per Share of Aurobindo Pharma is 2026 95.06 INR. EBITDA per Share of Aurobindo Pharma was 2025 123.23 INR. It decreases by -22.86% lower compared to the previous year.

The Aurobindo Pharma EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
130.67 INR
Jan 1, 2020
166.27 INR
Jan 1, 2021
178.48 INR
Jan 1, 2022
152.37 INR
Jan 1, 2023
160.17 INR
Jan 1, 2024
106.07 INR
Jan 1, 2025
123.23 INR
Jan 1, 2026
95.06 INR
The Aurobindo Pharma EBITDA per Share history
YEAREBITDA per ShareYoY
95.06INR-22.86%
123.23INR+16.19%
106.07INR-33.78%
160.17INR+5.12%
152.37INR-14.63%
178.48INR+7.34%
166.27INR+27.24%
130.67INR+6.65%
122.52INR+10.16%
111.22INR+8.11%
102.88INR+18.29%
86.97INR+0.34%
86.68INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aurobindo Pharma Stock analysis

What does Aurobindo Pharma do? Aurobindo Pharma Ltd is a global pharmaceutical company based in India. It was founded in 1986 by P.V. Ramprasad Reddy, K. Nityananda Reddy, and Kambhampati Hari Babu. It has become one of the leading companies in the industry over the past 35 years. The company's business model is based on the production and distribution of generics, active pharmaceutical ingredients, and biosimilars. It operates in several divisions, covering a wide range of products. Aurobindo Pharma's main division is the manufacturing of generics, including both simple generics and complex products like biosimilars. The company also produces a variety of pharmaceutical ingredients used in industries such as pharmacy, cosmetics, and food. In addition, Aurobindo is involved in the production of biosimilars, which are biological drugs that have similar properties to existing biological products. These products have the potential to improve access to life-saving medications and generate significant cost savings. Aurobindo also manufactures products for the veterinary medicine industry, including antibiotics, antiparasitics, and vitamins. The company has also established a strong presence in the American market in recent years through acquisitions and offers a wide range of products. It has also expanded its presence in Europe, Asia, and Africa. In 2020, Aurobindo Pharma played a significant role in combating the COVID-19 pandemic by introducing several medications that can be used to treat the virus, such as hydroxychloroquine and azithromycin for mild to moderate cases. The company has earned a reputation as a leader in the generics and active pharmaceutical ingredient markets and aims to provide high-quality medications at affordable prices, making a positive contribution to global health improvement. Aurobindo Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aurobindo Pharma stock

EBITDA per Share of Aurobindo Pharma is 95.06 INR in 2026.

EBITDA per Share of Aurobindo Pharma changed from 123.23 INR to 95.06 INR, representing a -22.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Aurobindo Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Aurobindo Pharma

All Key Metrics — Aurobindo Pharma